RT Journal Article
SR Electronic
T1 Device-assessed sleep and physical activity in individuals recovering from a hospital admission for COVID-19: a prospective, multicentre study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.03.22270391
DO 10.1101/2022.02.03.22270391
A1 ,
A1 Plekhanova, Tatiana
A1 Rowlands, Alex V
A1 Evans, Rachael A
A1 Edwardson, Charlotte L
A1 Bishop, Nicolette C
A1 Bolton, Charlotte E
A1 Chalmers, James D
A1 Davies, Melanie J
A1 Daynes, Enya
A1 Docherty, Annemarie B
A1 Elneima, Omer
A1 Greening, Neil J
A1 Greenwood, Sharlene A
A1 Hall, Andrew P
A1 Harris, Victoria C
A1 Harrison, Ewen M
A1 Henson, Joseph
A1 Ho, Ling-Pei
A1 Horsley, Alex
A1 Houchen-Wolloff, Linzy
A1 Khunti, Kamlesh
A1 Leavy, Olivia C
A1 Lone, Nazir I
A1 Marks, Michael
A1 Maylor, Ben
A1 McAuley, Hamish J C
A1 Nolan, Claire M
A1 Poinasamy, Krisnah
A1 Quint, Jennifer K
A1 Raman, Betty
A1 Richardson, Matthew
A1 Sargeant, Jack A
A1 Saunders, Ruth M
A1 Sereno, Marco
A1 Shikotra, Aarti
A1 Singapuri, Amisha
A1 Steiner, Michael
A1 Stensel, David J
A1 Wain, Louise V
A1 Whitney, Julie
A1 Wootton, Dan G
A1 Brightling, Christopher E
A1 Man, William D-C
A1 Singh, Sally J
A1 Yates, Tom
YR 2022
UL http://medrxiv.org/content/early/2022/02/03/2022.02.03.22270391.abstract
AB Objectives To describe physical behaviours following hospital admission for COVID-19 including associations with acute illness severity and ongoing symptoms.Methods 1077 patients with COVID-19 discharged from hospital between March and November 2020 were recruited. Using a 14-day wear protocol, wrist-worn accelerometers were sent to participants after a five-month follow-up assessment. Acute illness severity was assessed by the WHO clinical progression scale, and the severity of ongoing symptoms was assessed using four previously reported data-driven clinical recovery clusters. Two existing control populations of office workers and type 2 diabetes were comparators.Results Valid accelerometer data from 253 women and 462 men were included. Women engaged in a mean±SD of 14.9±14.7 minutes/day of moderate-to-vigorous physical activity (MVPA), with 725.6±104.9 minutes/day spent inactive and 7.22±1.08 hours/day asleep. The values for men were 21.0±22.3 and 755.5±102.8 minutes/day and 6.94±1.14 hours/day, respectively. Over 60% of women and men did not have any days containing a 30-minute bout of MVPA. Variability in sleep timing was approximately 2 hours in men and women. More severe acute illness was associated with lower total activity and MVPA in recovery. The very severe recovery cluster was associated with fewer days/week containing continuous bouts of MVPA, longer sleep duration, and higher variability in sleep timing. Patients post-hospitalisation with COVID-19 had lower levels of physical activity, greater sleep variability, and lower sleep efficiency than a similarly aged cohort of office workers or those with type 2 diabetes.Conclusions Physical activity and regulating sleep patterns are potential treatable traits for COVID-19 recovery programmes.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: CEBo reports grants from NUH Trust R&I / NIHR Nottingham BRC and Nottingham Hospital Charity, outside of the submitted work. SAG reports grants from NIHR clinical lectureship and Kidney Beam Trial funded by Kidney Research UK and being a member of global steering committee of the MFIT trial (Australia) and President UK Kidney Association, Joint Chair UK Kidney Research Consortium, outside of the submitted work. WD-CM reports grants from National Institute for Health Research and British Lung Foundation, personal fees from Mundipharma, Novartis, and European Conference and Incentive Services DMC, and being an advisory board member for Jazz Pharmaceuticals, outside of the submitted work. CMN reports being Co-chair of British Thoracic Society Pulmonary Rehabilitation Group, outside of the submitted work. JW reports grants from NIHR Programme Development Grant 2021 - Digital and Remote Enhancements for the Assessment and Management of older people living with frailty, and Kings College Hospital Charity 2020 - COVID-19 rehabilitation scoping work, outside of the submitted work. LHW reports grants from NIHR RfPB and ARC East Midlands, outside of the submitted work. JDC reports grants from Astrazeneca, Boehringer Ingelheim, Novartis, Gilead Sciences, Insmed, Glaxosmithkline, and fees for consultancy from Astrazeneca, Boehringer Ingelheim, Novartis, Zambon, Gilead Sciences, Insmed, Glaxosmithkline, Chiesi, outside of the submitted work. LPH reports grants from UKRI for UKILD study, MRC UK Regenerative Medicine Platform, Celgene (Immune mechanisms in fibrosis), British Lung Foundation (Immune drivers in Sarcoidosis), Boehnringer Ingleheim (IPF study), reports being on advisory board for CATALYST, phase 2 COVID platform trial and Chair of Respiratory Translational Research Collaboration, outside of the submitted work. AH reports grants from NIHR Manchester Biomedical Research Centre, during the conduct of the study and reports being Deputy Chair NIHR Translational Research Collaboration, outside of the submitted work. BR reports grants from British Heart Foundation Oxford Centre of Research Excellence, NIHR Oxford BRC and UKRI MRC during the conduct of the study, and fees for consultancy from Axcella Therapeutics, and payment from Axcella Therapeutics, outside of the submitted work. LVW reports grants from GSK and Orion Pharma, fees for consultancy from Galapagos, personal fees from Genentech, and being on advisory board for Galapagos, outside of the submitted work. RAE reports grants from NIHR, personal fees from Boehringer and Chiesi, and being European Respiratory Society Assembly 01.02 Pulmonary Rehabilitation secretary, outside of the submitted work. MJD is co-funded by the NIHR Leicester Biomedical Research Centre. TY reports grants from NIHR Leicester BRC during the conduct of the study, and grants from UKRI (MRC)-DHSC (NIHR) COVID19 Rapid Response Rolling Call (MR/V020536/1) and from HDR-UK (HDRUK2020.138), outside of the submitted work. KK reports being Chair of the Ethnicity Subgroup of the UK Scientific Advisory Group for Emergencies (SAGE). DGW is supported by an NIHR Advanced Fellowship. CEB reports grants from Grants from GSK, AZ, Sanofi, BI, Chiesi, Novartis, Roche, Genentech, Mologic, 4DPharma, fees to institution for consultancy GSK, AZ, Sanofi, BI, Chiesi, Novartis, Roche, Genentech, Mologic, 4DPharma, TEVA. All other authors declare no competing interests.Funding StatementJointly funded by UK Research and Innovation and National Institute of Health Research (grant references: MR/V027859/1 and COV0319).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Leeds West Research Ethics Committee (20/YH/0225) gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe protocol, consent form, definition and derivation of clinical characteristics and outcomes, training materials, regulatory documents, information about requests for data access, and other relevant study materials are available online https://www.phosp.org/. https://www.phosp.org/